Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Lipid-Polyglutamate Nanoparticle Vaccine Platform

ACS Applied Materials & Interfaces(2021)10.1021/acsami.0c20607Source: DataRank Database

Lipid-Polyglutamate Nanoparticle Vaccine Platform is a research paper published in ACS Applied Materials & Interfaces (2021). On theSindex it has a DataRank of 0. It has been cited 39 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access39 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.13)OA: greenTopics (85)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (18)

Alessio Malfanti ORCID,Kim Deswarte ORCID,Kaloian Koynov ORCID,Bianka Golba ORCID,Tingting Ye

Live enrichment

PubMed:33507728 PMC:PMC7116839 OpenAlex:https://openalex.org/W3121304284

H2020 European Research Council

Grant: ERC-CoG-2014-648831 and ERC-PoC-2018-825798

Spanish Ministry of Science and Innovation

Grant: SAF2016-80427-R and PID2019-108806RB-I00

European Research Council

Grant: 648831

Towards the design of Personalised Polymer-based Combination Nanomedicines for Advanced Stage Breast Cancer Patients

European Research Council

Grant: 817938

Synergistic engineering of anti-tumor immunity by synthetic biomaterials

European Research Council

Grant: 825798

Off-the-Shelf Polypeptide-based Immunotherapy for Advanced Melanoma Treatment

FWCI

2.13

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: other-oa

repositoryhttp://hdl.handle.net/2078.1/255658

publisherhttps://pubs.acs.org/doi/pdf/10.1021/acsami.0c20607

journalhttps://doi.org/10.1021/acsami.0c20607

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33507728

Fields of Study

Immunotherapy and Immune ResponsesRNA Interference and Gene DeliveryImmune Response and Inflammation02 engineering and technology01 natural sciences0104 chemical sciences0210 nano-technologyAdjuvants, ImmunologicAnimalsCell LineLipidsLymphocytesMiceMice, Inbred BALB CMolecular StructureNanoparticlesParticle SizePolyglutamic AcidRAW 264.7 CellsSurface PropertiesVaccines

MeSH Terms

RAW 264.7 CellsAdjuvants, ImmunologicAnimalsCell LineLipidsLymphocytesMice, Inbred BALB CParticle SizePolyglutamic AcidSurface PropertiesVaccinesMolecular StructureMiceNanoparticles

Keywords

AdjuvantAntigenImmune systemPeptideInnate immune systemMaterials scienceBiologyBiochemistryImmunologyVaccinePeptidesLipid NanoparticlesTlr AgonistsLNPChemical Sciences not elsewhere classifiedSurface PropertiesAg-specific T cells responsesPGA-IMDQMicrobiologyIMDQCell LineMiceSpace ScienceAdjuvants, ImmunologiclipidTLRAnimalsLymphocytesParticle Sizelymphoid tissueMolecular BiologyCancerpeptide antigenMice, Inbred BALB CVaccinesMolecular StructurePGALipid-Polyglutamate Nanoparticle Va.Computational BiologynatureCell BiologyLipidsvaccine; lipid nanoparticles; peptides; TLR agonistsRAW 264.7 CellsPolyglutamic AcidMedicineNanoparticlesacidBiotechnologyBiological Sciences not elsewhere classified

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being